Form 8-K - Current report:
SEC Accession No. 0001214659-25-010830
Filing Date
2025-07-23
Accepted
2025-07-23 16:30:41
Documents
14
Period of Report
2025-07-23
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 i7232518k.htm   iXBRL 8-K 27684
2 EXHIBIT 99.1 ex99_1.htm EX-99.1 17440
6 GRAPHIC alzamendlogo_regmark.jpg GRAPHIC 17222
  Complete submission text file 0001214659-25-010830.txt   244226

Data Files

Seq Description Document Type Size
3 XBRL SCHEMA FILE alzn-20250723.xsd EX-101.SCH 2990
4 XBRL LABEL FILE alzn-20250723_lab.xml EX-101.LAB 34239
5 XBRL PRESENTATION FILE alzn-20250723_pre.xml EX-101.PRE 22342
16 EXTRACTED XBRL INSTANCE DOCUMENT i7232518k_htm.xml XML 3914
Mailing Address 3500 LENOX RD. NE SUITE 1500 ATLANTA GA 30326
Business Address 3500 LENOX RD. NE SUITE 1500 ATLANTA GA 30326 844-722-6333
Alzamend Neuro, Inc. (Filer) CIK: 0001677077 (see all company filings)

EIN.: 811822909 | State of Incorp.: DE | Fiscal Year End: 0430
Type: 8-K | Act: 34 | File No.: 001-40483 | Film No.: 251143436
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)